CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Ceftriaxone Sodium

头孢曲松钠 杂质对照品Ceftriaxone Sodium Impurities

EP29 个杂质条目29 impurity entries

本页汇总 头孢曲松钠 的 29 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 29 impurity reference standards of Ceftriaxone Sodium with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 头孢曲松钠(Ceftriaxone Sodium)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesA critical review of chromatographic techniques for impurity profiling and stability-indicating analysis of ceftriaxone sodium
    Drug development and industrial pharmacy · 2025 · Srour A et al.  ·  PMID 41030022  ·  DOI
  2. 杂质研究Impurity studiesA Clean, Sustainable and Stability-Indicating Method for the Quantification of Ceftriaxone Sodium in Pharmaceutical Product by HPLC
    Journal of chromatographic science · 2022 · da Trindade MT et al.  ·  PMID 34131704  ·  DOI
  3. 杂质研究Impurity studiesThe Role of an Impurity in Ceftriaxone Sodium Preparation for Injection in Determining Compatibility with Calcium-Containing Solutions
    Chemical & pharmaceutical bulletin · 2016 · Tange M et al.  ·  PMID 26936047  ·  DOI
  4. 分析方法Analytical MethodsA high-performance thin-layer chromatography densitometric method for the separation of isomeric ceftriaxone in powder for injection formulation
    Scientific reports · 2024 · Mwamwitwa KW et al.  ·  PMID 39487191  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisControllable synthesis of porous boron nitride fibers modified by cobalt and nickel oxides for efficient ceftriaxone sodium adsorption from aqueous solution
    Nanotechnology · 2024 · Wang D et al.  ·  PMID 39191264  ·  DOI

头孢曲松钠 —— 原料药与杂质对照品Ceftriaxone Sodium — drug substance & impurities

共 29 个条目(含原料药本体)29 items incl. the drug substance
Ceftriaxone Sodium Impurity 1 Monomer (Ceftriaxone Sodium EP Impurity A) ((E)-Ceftriaxone) structure
EPA
头孢曲松钠杂质1 单体 (头孢曲松钠EP杂质A) ((E)-头孢曲松)Ceftriaxone Sodium Impurity 1 Monomer (Ceftriaxone Sodium EP Impurity A) ((E)-Ceftriaxone)
Ceftriaxone Sodium Impurity 1 Monomer (Ceftriaxone Sodium EP Impurity A) ((E)-Ceftriaxone)
CAS No.92143-31-2
Chemical FormulaC18H18N8O7S3
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 1 (Ceftriaxone Sodium EP Impurity A Disodium Salt) ((E)-Ceftriaxone Disodium) structure
EPA
头孢曲松钠杂质1 (头孢曲松钠EP杂质A 二钠盐) ((E)-头孢曲松二钠)Ceftriaxone Sodium Impurity 1 (Ceftriaxone Sodium EP Impurity A Disodium Salt) ((E)-Ceftriaxone Disodium)
Ceftriaxone Sodium Impurity 1 (Ceftriaxone Sodium EP Impurity A Disodium Salt) ((E)-Ceftriaxone Disodium)
CAS No.97164-54-0
Chemical FormulaC18H16N8Na2O7S3
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 3 (Ceftriaxone Sodium EP Impurity C) structure
EPC
头孢曲松钠杂质3 (头孢曲松钠EP杂质C)Ceftriaxone Sodium Impurity 3 (Ceftriaxone Sodium EP Impurity C)
Ceftriaxone Sodium Impurity 3 (Ceftriaxone Sodium EP Impurity C)
CAS No.58909-39-0
Chemical FormulaC4H5N3O2S
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 4 (Ceftriaxone Sodium EP Impurity D) structure
EPD
头孢曲松钠杂质4 (头孢曲松钠EP杂质D)Ceftriaxone Sodium Impurity 4 (Ceftriaxone Sodium EP Impurity D)
Ceftriaxone Sodium Impurity 4 (Ceftriaxone Sodium EP Impurity D)
CAS No.80756-85-0
Chemical FormulaC13H10N4O2S3
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 5 (Ceftriaxone Sodium EP Impurity E Sodium Salt) structure
EPE
头孢曲松钠杂质5 (头孢曲松钠EP杂质E 钠盐)Ceftriaxone Sodium Impurity 5 (Ceftriaxone Sodium EP Impurity E Sodium Salt)
Ceftriaxone Sodium Impurity 5 (Ceftriaxone Sodium EP Impurity E Sodium Salt)
CAS No.2227256-62-2
Chemical FormulaC12H12N5O5S2-·Na+
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 5 Monomer (Ceftriaxone Sodium EP Impurity E) structure
EPE
头孢曲松钠杂质5 单体 (头孢曲松钠EP杂质E)Ceftriaxone Sodium Impurity 5 Monomer (Ceftriaxone Sodium EP Impurity E)
Ceftriaxone Sodium Impurity 5 Monomer (Ceftriaxone Sodium EP Impurity E)
CAS No.58909-56-1
Chemical FormulaC12H13N5O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Disodium Hemiheptahydrate structure
—
头孢曲松二钠三倍半水合物Ceftriaxone Disodium Hemiheptahydrate
Ceftriaxone Disodium Hemiheptahydrate
CAS No.104376-79-6
Chemical FormulaC18H16N8O7S32-·2Na+·7/2H2O
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone structure
—
头孢曲松Ceftriaxone
Ceftriaxone
CAS No.73384-59-5
Chemical FormulaC18H18N8O7S3
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Disodium structure
—
头孢曲松二钠Ceftriaxone Disodium
Ceftriaxone Disodium
CAS No.74578-69-1
Chemical FormulaC18H16N8Na2O7S3
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 8 Sodium Salt structure
8
头孢曲松钠杂质8 钠盐Ceftriaxone Sodium Impurity 8 Sodium Salt
Ceftriaxone Sodium Impurity 8 Sodium Salt
CAS No.51762-04-0
Chemical FormulaC16H20N3O8S-·Na+
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 8 structure
8
头孢曲松钠杂质8Ceftriaxone Sodium Impurity 8
Ceftriaxone Sodium Impurity 8
CAS No.59143-60-1
Chemical FormulaC16H19N3O8SZn
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 10 structure
10
头孢曲松钠杂质10Ceftriaxone Sodium Impurity 10
Ceftriaxone Sodium Impurity 10
CAS No.6938-68-7
Chemical FormulaC2H7N3S
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 12 Sodium Salt structure
12
头孢曲松钠杂质12 钠盐Ceftriaxone Sodium Impurity 12 Sodium Salt
Ceftriaxone Sodium Impurity 12 Sodium Salt
CAS No.62-76-0
Chemical FormulaC2H2O4·2Na
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 13 structure
13
头孢曲松钠杂质13Ceftriaxone Sodium Impurity 13
Ceftriaxone Sodium Impurity 13
CAS No.120-78-5
Chemical FormulaC14H8N2S4
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 14 structure
14
头孢曲松钠杂质14Ceftriaxone Sodium Impurity 14
Ceftriaxone Sodium Impurity 14
CAS No.65872-41-5
Chemical FormulaC6H7N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 15 structure
15
头孢曲松钠杂质15Ceftriaxone Sodium Impurity 15
Ceftriaxone Sodium Impurity 15
CAS No.66341-09-1
Chemical FormulaC6H7N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 21 (EDTA Disodium) structure
21
头孢曲松钠杂质21 (乙二胺四乙酸二钠)Ceftriaxone Sodium Impurity 21 (EDTA Disodium)
Ceftriaxone Sodium Impurity 21 (EDTA Disodium)
CAS No.139-33-3
Chemical FormulaC10H14N2O82-·2Na+
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 21 Dihydrate CRS (EDTA Disodium Dihydrate CRS) structure
21
头孢曲松钠杂质21 二水合物 CRS (乙二胺四乙酸二钠二水合物 CRS)Ceftriaxone Sodium Impurity 21 Dihydrate CRS (EDTA Disodium Dihydrate CRS)
Ceftriaxone Sodium Impurity 21 Dihydrate CRS (EDTA Disodium Dihydrate CRS)
CAS No.6381-92-6
Chemical FormulaC10H14N2O82-·2Na+·2H2O
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 22 structure
22
头孢曲松钠杂质22Ceftriaxone Sodium Impurity 22
Ceftriaxone Sodium Impurity 22
CAS No.15690-38-7
Chemical FormulaC8H10N2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 24 structure
24
头孢曲松钠杂质24Ceftriaxone Sodium Impurity 24
Ceftriaxone Sodium Impurity 24
CAS No.18884-65-6
Chemical FormulaC10H12N2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 25 structure
25
头孢曲松钠杂质25Ceftriaxone Sodium Impurity 25
Ceftriaxone Sodium Impurity 25
CAS No.97466-28-9
Chemical FormulaC18H18N8O8S3
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 26 structure
26
头孢曲松钠杂质26Ceftriaxone Sodium Impurity 26
Ceftriaxone Sodium Impurity 26
CAS No.1684396-27-7
Chemical FormulaC13H10N4O2S3
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 28 structure
28
头孢曲松钠杂质28Ceftriaxone Sodium Impurity 28
Ceftriaxone Sodium Impurity 28
CAS No.1621913-67-4
Chemical FormulaC19H18N8O9S3
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 33 structure
33
头孢曲松钠杂质33Ceftriaxone Sodium Impurity 33
Ceftriaxone Sodium Impurity 33
CAS No.111298-82-9
Chemical FormulaC14H15N3O5S3
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 37 structure
37
头孢曲松钠杂质37Ceftriaxone Sodium Impurity 37
Ceftriaxone Sodium Impurity 37
CAS No.1637561-91-1
Chemical FormulaC18H18N8O7S3
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 56 structure
56
头孢曲松钠杂质56Ceftriaxone Sodium Impurity 56
Ceftriaxone Sodium Impurity 56
CAS No.2630907-68-3
Chemical FormulaC18H18N8O7S3
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 60 structure
60
头孢曲松钠杂质60Ceftriaxone Sodium Impurity 60
Ceftriaxone Sodium Impurity 60
CAS No.64018-22-0
Chemical FormulaC18H13O6PS22-·2Na+
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 71 structure
71
头孢曲松钠杂质71Ceftriaxone Sodium Impurity 71
Ceftriaxone Sodium Impurity 71
CAS No.86619-88-7
Chemical FormulaC13H15N5O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Ceftriaxone Sodium Impurity 72 structure
72
头孢曲松钠杂质72Ceftriaxone Sodium Impurity 72
Ceftriaxone Sodium Impurity 72
CAS No.1201851-24-2
Chemical FormulaC6H8N4O2S
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

头孢曲松钠 —— 研究文献与合成路线Ceftriaxone Sodium — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 头孢曲松钠 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Ceftriaxone Sodium. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Development and Validation of Stability Indicating Spectroscopic Method for Content Analysis of Ceftriaxone Sodium in Pharmaceuticals
    Ethiraj R, Thiruvengadam E, Sampath VS, et al. · International scholarly research notices · 2014 · 被引 9cited 9
  2. A critical review of chromatographic techniques for impurity profiling and stability-indicating analysis of ceftriaxone sodium
    Srour A, Arous B, Al-Mardini MA · Drug development and industrial pharmacy · 2025 · 被引 1cited 1
  3. The Role of an Impurity in Ceftriaxone Sodium Preparation for Injection in Determining Compatibility with Calcium-Containing Solutions
    Tange M, Yoshida M, Nakai Y, et al. · Chemical & pharmaceutical bulletin · 2016 · 被引 9cited 9
  4. Ceftriaxone sodium degradation by carbon quantum dots (CQDs)-decorated C-doped α-Bi2O3 nanorods
    Sun X, Pan Y, Song Y, et al. · Environmental science and ecotechnology · 2023 · 被引 4cited 4
  5. A Clean, Sustainable and Stability-Indicating Method for the Quantification of Ceftriaxone Sodium in Pharmaceutical Product by HPLC
    da Trindade MT, Kogawa AC, Salgado HRN · Journal of chromatographic science · 2022 · 被引 10cited 10
  6. Validation of an HPLC-UV method for the determination of ceftriaxone sodium residues on stainless steel surface of pharmaceutical manufacturing equipments
    Akl MA, Ahmed MA, Ramadan A · Journal of pharmaceutical and biomedical analysis · 2011 · 被引 21cited 21

合成与制备工艺专利Synthesis & process patents

  1. METHOD FOR PRODUCING INJECTABLE PREPARATION CONTAINING CEFTRIAXONE SODIUM AND TAZOBACTAM SODIUM
    HAN YUDONG, HAN KESHENG, XU LIGUI · 公开号 WO2010124601WO2010124601 · 2010
  2. Process for preparing ceftriaxone sodium
    ZHAO YUSHAN, MIAO DEZU, LIU WEI · 公开号 CN1634933CN1634933 · 2005
  3. Refining process for crude product of ceftriaxone sodium
    YUSHAN ZHAO, DEZU MIAO, LONGKE WANG, JIHONG KONG, et al. · 公开号 CN101289458CN101289458 · 2008
  4. IMPROVED PROCESS FOR THE MANUFACTURE OF CEFTRIAXONE SODIUM
    JAWEED MUKARRAM SIDDIQUI MOHAMMED, NAITHANI PANKAJ KUMAR, PUROHIT MANISH, POKALWAR RAJKUMAR UDHAVRAO · 公开号 WO2005105813WO2005105813 · 2005

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

头孢曲松钠 杂质谱研究要点Ceftriaxone Sodium — impurity profiling notes

下面这些是拿到 头孢曲松钠 的 29 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 29 impurity entries for Ceftriaxone Sodium, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances